LIVIVO - Search results -

Search results

Result 1 - 10 of total 1762

Search options

Article ; Online: Targeting the PI3K signaling pathway in cancer therapy.

Bartholomeusz, Chandra / Gonzalez-Angulo, Ana Maria

2012 Volume 16, Issue 1, Page(s) 121–130

Abstract: ... types of human cancer.: Expert opinion: Small-molecule inhibitors targeting the PI3K/Akt/mTOR pathway ... Introduction: The PI3K signaling pathway is involved in the regulation of cancer cell growth ... Areas covered: The genetic alterations in the PI3K/mammalian target of rapamycin (mTOR)/Akt pathway ...

Abstract	Introduction: The PI3K signaling pathway is involved in the regulation of cancer cell growth, motility, survival and metabolism. The pathway is frequently active in many different types of cancer-e.g., breast, bladder, prostate, thyroid, ovarian and NSCLC. Targetable genetic aberrations in this pathway give us many opportunities for development of targeted therapies for different types of cancer. Areas covered: The genetic alterations in the PI3K/mammalian target of rapamycin (mTOR)/Akt pathway, as well as the drugs that target this pathway, either alone, in combination with other targeted agents or in chemotherapy. Targeted inhibitors of the PI3K pathway currently being tested in clinical trials in different types of human cancer. Expert opinion: Small-molecule inhibitors targeting the PI3K/Akt/mTOR pathway show some success with these agents in current clinical trials. For further improvement in response, molecular correlates that can be used for patient selection, need to be determined. A more efficient and effective way to screen for patients to determine which patients are most likely to benefit from PI3K pathway inhibitors is also needed.
MeSH term(s)	Animals ; Antineoplastic Agents/therapeutic use ; Humans ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/metabolism ; Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Signal Transduction/drug effects
Chemical Substances	Antineoplastic Agents ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-)
Language	English
Publishing date	2012-01
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2055208-7
ISSN	1744-7631 ; 1472-8222
ISSN (online)	1744-7631
ISSN	1472-8222
DOI	10.1517/14728222.2011.644788
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5244: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Targeting the PI3K signaling pathway in cancer.

Wong, Kwok-Kin / Engelman, Jeffrey A / Cantley, Lewis C

Current opinion in genetics & development

2009 Volume 20, Issue 1, Page(s) 87–90

Abstract: The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers ... with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway. ... In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically ...

Abstract	The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; MAP Kinase Kinase Kinases ; Neoplasms/drug therapy ; Phosphatidylinositol 3-Kinases/genetics ; Phosphoinositide-3 Kinase Inhibitors ; Receptor, ErbB-2/antagonists & inhibitors ; Signal Transduction/drug effects
Chemical Substances	Antineoplastic Agents ; Phosphoinositide-3 Kinase Inhibitors ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; MAP Kinase Kinase Kinases (EC 2.7.11.25)
Language	English
Publishing date	2009-12-16
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1077312-5
ISSN	1879-0380 ; 0959-437X
ISSN (online)	1879-0380
ISSN	0959-437X
DOI	10.1016/j.gde.2009.11.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer.

Morgos, Diana-Theodora / Stefani, Constantin / Miricescu, Daniela / Greabu, Maria / Stanciu, Silviu / Nica, Silvia / Stanescu-Spinu, Iulia-Ioana / Balan, Daniela Gabriela / Balcangiu-Stroescu, Andra-Elena / Coculescu, Elena-Claudia / Georgescu, Dragos-Eugen / Nica, Remus Iulian

International journal of molecular sciences

2024 Volume 25, Issue 3

Abstract: Gastric cancer (GC) is the fourth leading cause of death worldwide, with more than 1 million cases ...

Abstract	Gastric cancer (GC) is the fourth leading cause of death worldwide, with more than 1 million cases diagnosed every year.
MeSH term(s)	Humans ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphatidylinositol 3-Kinase/metabolism ; Sirolimus ; Phosphatidylinositol 3-Kinases/metabolism ; Stomach Neoplasms/etiology ; Stomach Neoplasms/genetics ; TOR Serine-Threonine Kinases/metabolism ; MAP Kinase Signaling System
Chemical Substances	Proto-Oncogene Proteins c-akt (EC 2.7.11.1) ; Phosphatidylinositol 3-Kinase (EC 2.7.1.137) ; Sirolimus (W36ZG6FT64) ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; TOR Serine-Threonine Kinases (EC 2.7.11.1)
Language	English
Publishing date	2024-02-03
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms25031848
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: MiRNA-766-3p inhibits gastric cancer via targeting COL1A1 and regulating PI3K/AKT signaling pathway.

Ding, Yujie / Zhang, Mengyuan / Hu, Sheng / Zhang, Caiyun / Zhou, Yue / Han, Ming / Li, Jingjing / Li, Fulong / Ni, Hongmei / Fang, Shengquan / Chen, Qilong

Journal of Cancer

2024 Volume 15, Issue 4, Page(s) 990–998

Abstract: ... ...

Abstract	Objective
Language	English
Publishing date	2024-01-01
Publishing country	Australia
Document type	Journal Article
ZDB-ID	2573318-7
ISSN	1837-9664
ISSN	1837-9664
DOI	10.7150/jca.90321
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: MicroRNA-130b Suppresses Malignant Behaviours and Inhibits the Activation of the PI3K/Akt Signaling Pathway by Targeting MET in Pancreatic Cancer.

Yang, Zilin / Tang, Yuming / Wu, Xuejiao / Wang, Jiancheng / Yao, Weiyan

Biochemical genetics

2024

Abstract: ... cell proliferation, migration, promoted apoptosis, and inhibited the PI3K/Akt pathway by targeting MET in PC cells ... There has been interested in the microRNAs' roles in pancreatic cancer (PC) cell biology ... particularly in regulating pathways related to tumorigenesis. The study aimed to explore the hub miRNAs in PC ...

Abstract	There has been interested in the microRNAs' roles in pancreatic cancer (PC) cell biology, particularly in regulating pathways related to tumorigenesis. The study aimed to explore the hub miRNAs in PC and underlying mechanisms by bioinformatics and fundamental experiments. RNA datasets collected from the Gene Expression Omnibus were analysed to find out differentially expressed RNAs (DERNAs). The miRNA-mRNA and protein-protein interaction (PPI) networks were built. The clinicopathological features and expressions of hub miRNAs and hub mRNAs were explored. Dual-luciferase reporter gene assay was performed to assess the interaction between microRNA and target gene. RT-qPCR and western blot were employed to explore RNA expression. The roles of RNA were detected by CCK-8 test, wound healing, transwell, and flow cytometry experiment. We verified 40 DEmiRNAs and 1613 DEmRNAs, then detected a total of 69 final functional mRNAs (FmRNAs) and 23 DEmiRNAs. In the miRNA-mRNA networks, microRNA-130b (miR-130b) was the hub RNA with highest degrees. Clinical analysis revealed that miR-130b was considerably lower expressed in cancerous tissues than in healthy ones, and patients with higher-expressed miR-130b had a better prognosis. Mechanically, miR-130b directly targeted MET in PC cells. Cell functional experiments verified that miR-130b suppressed cell proliferation, migration, promoted apoptosis, and inhibited the PI3K/Akt pathway by targeting MET in PC cells. Our findings illustrated the specific molecular mechanism of miR-130b regulating PC progress. The miR-130b/MET axis may be an alternative target in the therapeutic intervention of PC and provide an opportunity to deepen our understanding of the pathogenesis of PC.
Language	English
Publishing date	2024-04-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	2168-4
ISSN	1573-4927 ; 0006-2928
ISSN (online)	1573-4927
ISSN	0006-2928
DOI	10.1007/s10528-024-10696-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.

Leiphrakpam, Premila D / Are, Chandrakanth

International journal of molecular sciences

2024 Volume 25, Issue 6

Abstract: ... B/mammalian target of the rapamycin (PI3K/Akt/mTOR) signaling pathway axis is a major pathway ... to provide an overview of the role of the PI3K/Akt/mTOR signaling pathway axis in driving CRC, existing PI3K ... In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer (CRC ...

Abstract	In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer (CRC) treatment strategies. This type of therapy targets a tumor-vulnerable spot formed primarily due to an alteration in an oncogene and/or a tumor suppressor gene. However, tumor heterogeneity in CRC frequently results in treatment resistance, underscoring the need to understand the molecular mechanisms involved in CRC for the development of novel targeted therapies. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/Akt/mTOR) signaling pathway axis is a major pathway altered in CRC. The aberrant activation of this pathway is associated with CRC initiation, progression, and metastasis and is critical for the development of drug resistance in CRC. Several drugs target PI3K/Akt/mTOR in clinical trials, alone or in combination, for the treatment of CRC. This review aims to provide an overview of the role of the PI3K/Akt/mTOR signaling pathway axis in driving CRC, existing PI3K/Akt/mTOR-targeted agents against CRC, their limitations, and future trends.
MeSH term(s)	Humans ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphoinositide-3 Kinase Inhibitors ; Signal Transduction ; TOR Serine-Threonine Kinases/metabolism ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/metabolism
Chemical Substances	Proto-Oncogene Proteins c-akt (EC 2.7.11.1) ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Phosphoinositide-3 Kinase Inhibitors ; TOR Serine-Threonine Kinases (EC 2.7.11.1)
Language	English
Publishing date	2024-03-09
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms25063178
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Treating non-small cell lung cancer by targeting the PI3K signaling pathway.

Jiang, Lin / Zhang, Jingbo / Xu, Yan / Xu, Heng / Wang, Mengzhao

Chinese medical journal

2022 Volume 135, Issue 11, Page(s) 1272–1284

Abstract: Abstract: The phosphosphatidylinositol-3-kinase (PI3K) signaling pathway is one of the most ... focuses on the role of the PI3K signaling pathway in the occurrence and development of NSCLC and ... an increasing number of studies on NSCLC and PI3K signaling pathways. Inhibitors of various parts of the PI3K ...

Abstract	Abstract: The phosphosphatidylinositol-3-kinase (PI3K) signaling pathway is one of the most important intracellular signal transduction pathways affecting cell functions, such as apoptosis, translation, metabolism, and angiogenesis. Lung cancer is a malignant tumor with the highest morbidity and mortality rates in the world. It can be divided into two groups, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for >85% of all lung cancers. There are currently many clinical treatment options for NSCLC; however, traditional methods such as surgery, chemotherapy, and radiotherapy have not been able to provide patients with good survival benefits. The emergence of molecular target therapy has improved the survival and prognosis of patients with NSCLC. In recent years, there have been an increasing number of studies on NSCLC and PI3K signaling pathways. Inhibitors of various parts of the PI3K pathway have appeared in various phases of clinical trials with NSCLC as an indication. This article focuses on the role of the PI3K signaling pathway in the occurrence and development of NSCLC and summarizes the current clinical research progress and possible development strategies.
MeSH term(s)	Apoptosis ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Proliferation ; Humans ; Lung Neoplasms/pathology ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction
Chemical Substances	Proto-Oncogene Proteins c-akt (EC 2.7.11.1)
Language	English
Publishing date	2022-06-05
Publishing country	China
Document type	Journal Article
ZDB-ID	127089-8
ISSN	2542-5641 ; 0366-6999 ; 1002-0187
ISSN (online)	2542-5641
ISSN	0366-6999 ; 1002-0187
DOI	10.1097/CM9.0000000000002195
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1207: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Ua VI Zs.425: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The FOXO1/G6PC axis promotes gastric cancer progression and mediates 5-fluorouracil resistance by targeting the PI3K/AKT/mTOR signaling pathway.

Han, Anna / Liu, Taorui / Du, Pan / Wang, Mengying / Liu, Jiajing / Chen, Liyan

Molecular carcinogenesis

2024 Volume 63, Issue 4, Page(s) 688–700

Abstract: ... cell proliferation, metastasis, and 5-Fluorouracil (5-FU) resistance by targeting the PI3K/AKT/mTOR signaling pathway ... Gastric cancer (GC) is a prevalent malignancy of the digestive system. Distant metastasis and ...

Abstract	Gastric cancer (GC) is a prevalent malignancy of the digestive system. Distant metastasis and chemotherapy resistance are the crucial obstacles to prognosis in GC. Recent research has discovered that the glucose-6-phosphatase catalytic subunit (G6PC) plays an important role in tumor malignant development. However, little evidence has highlighted its role in GC. Herein, through a comprehensive analysis including profiling of tissue samples and functional validation in vivo and in vitro, we identify G6PC as a crucial factor in GC tumorigenesis. Importantly, we found that the FOXO1/G6PC axis could accelerate GC cell proliferation, metastasis, and 5-Fluorouracil (5-FU) resistance by targeting the PI3K/AKT/mTOR signaling pathway, implicating that as a prospective therapeutic approach in GC.
MeSH term(s)	Humans ; Stomach Neoplasms/pathology ; Proto-Oncogene Proteins c-akt/metabolism ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Phosphatidylinositol 3-Kinases/metabolism ; Signal Transduction ; TOR Serine-Threonine Kinases/genetics ; TOR Serine-Threonine Kinases/metabolism ; Cell Line, Tumor ; Cell Proliferation ; Forkhead Box Protein O1/genetics ; Forkhead Box Protein O1/metabolism
Chemical Substances	Proto-Oncogene Proteins c-akt (EC 2.7.11.1) ; Fluorouracil (U3P01618RT) ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; TOR Serine-Threonine Kinases (EC 2.7.11.1) ; FOXO1 protein, human ; Forkhead Box Protein O1
Language	English
Publishing date	2024-01-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	1004029-8
ISSN	1098-2744 ; 0899-1987
ISSN (online)	1098-2744
ISSN	0899-1987
DOI	10.1002/mc.23681
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2664: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Retraction: MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway.

Frontiers in oncology

2023 Volume 13, Page(s) 1298871

Abstract: This retracts the article DOI: 10.3389/fonc.2019.00653.]. ...

Abstract	[This retracts the article DOI: 10.3389/fonc.2019.00653.].
Language	English
Publishing date	2023-10-10
Publishing country	Switzerland
Document type	Retraction of Publication
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2023.1298871
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: [Retracted] Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer.

Liu, Tao / Liang, Xiangsen / Sun, Yu / Yang, Shengzhuang

Experimental and therapeutic medicine

2023 Volume 27, Issue 1, Page(s) 1

Abstract: This retracts the article DOI: 10.3892/etm.2021.10624.]. ...

Abstract	[This retracts the article DOI: 10.3892/etm.2021.10624.].
Language	English
Publishing date	2023-11-06
Publishing country	Greece
Document type	Retraction of Publication
ZDB-ID	2683844-8
ISSN	1792-1015 ; 1792-0981
ISSN (online)	1792-1015
ISSN	1792-0981
DOI	10.3892/etm.2023.12288
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito